Xilio Development Inc (XLO)

Currency in USD
7.920
+0.130(+1.67%)
Closed·
7.9200.000(0.00%)
·
Earnings results expected in 6 days
XLO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.6508.070
52 wk Range
6.46516.520
Key Statistics
Prev. Close
7.79
Open
7.74
Day's Range
7.65-8.07
52 wk Range
6.465-16.52
Volume
25.2K
Average Vol. (3m)
38.54K
1-Year Change
-27.5698%
Book Value / Share
9.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XLO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.000
Upside
+152.53%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Xilio Development Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.000
(+152.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy2.00-74.75%-New CoverageAug 06, 2025

Earnings

Latest Release
Mar 16, 2026
EPS / Forecast
0.81 / -0.07
Revenue / Forecast
13.69M / 10.9M
EPS Revisions
Last 90 days

XLO Income Statement

Compare XLO to Peers and Sector

Metrics to compare
XLO
Peers
Sector
Relationship
P/E Ratio
−1.3x−6.2x−0.5x
PEG Ratio
−0.030.010.00
Price / Book
1.3x3.3x2.6x
Price / LTM Sales
1.0x7.8x3.2x
Upside (Analyst Target)
156.7%48.7%48.8%
Fair Value Upside
Unlock8.4%6.9%Unlock

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
158.62K2.74%1.24M
Other Institutional Investors
4.22M73.05%32.90M
Public Companies & Retail Investors
1.40M24.21%10.91M
Total
5.78M100.00%45.05M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gilead Sciences, Inc.11.25%650,3905,067
Frazier Life Sciences Management, LP7.31%422,5073,291

People Also Watch

6.810
UGRO
+9.84%
34.60
FLY
+3.31%
164.460
AAOI
+7.61%
7.12
POET
+7.88%
25.34
LUNR
+2.22%

FAQ

What Is the Xilio Development (XLO) Stock Price Today?

The Xilio Development stock price today is 7.920 USD.

What Stock Exchange Does Xilio Development Trade On?

Xilio Development is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Xilio Development?

The stock symbol for Xilio Development is "XLO."

What Is the Xilio Development Market Cap?

As of today, Xilio Development market cap is 45.050M USD.

What Is Xilio Development's Earnings Per Share (TTM)?

The Xilio Development EPS (TTM) is -7.733.

When Is the Next Xilio Development Earnings Date?

Xilio Development will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is XLO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Xilio Development Stock Split?

Xilio Development has split 1 times.

How Many Employees Does Xilio Development Have?

Xilio Development has 76 employees.

What is the current trading status of Xilio Development (XLO)?

As of May 01, 2026, Xilio Development (XLO) is trading at a price of 7.920 USD, with a previous close of 7.790 USD. The stock has fluctuated within a day range of 7.650 USD to 8.070 USD, while its 52-week range spans from 6.465 USD to 16.520 USD.

What Is Xilio Development (XLO) Price Target According to Analysts?

The average 12-month price target for Xilio Development is 20.000 USD, with a high estimate of 20 USD and a low estimate of 20 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +152.53% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.